Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323278 | PMC |
| http://dx.doi.org/10.21037/tau.2018.11.07 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy.
Urol Oncol
December 2024
Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo and Carlo, Via A. Di Rudini 8, Milan 20142, Italy. Electronic address:
Article Synopsis
- The study examines the impact of smoking on the outcomes of nonmuscle invasive bladder cancer (NMIBC) treated with BCG instillations, indicating that smokers may have poorer results.
- Approximately 1,313 patients were analyzed using a statistical model to correlate smoking history with disease progression, revealing that heavy smokers have over double the risk of disease progression compared to nonsmokers.
- The results highlight the importance of considering a patient's smoking history in NMIBC management and the necessity for tailored smoking cessation strategies in treatment plans.
Assessing the influence of smoking on inflammatory markers in bacillus Calmette Guérin response among bladder cancer patients: a novel machine-learning approach.
Minerva Urol Nephrol
December 2024
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Article Synopsis
- About 70% of bladder cancer cases are non-muscle invasive (NMIBC) and inflammation, influenced by factors like smoking, affects treatment outcomes with BCG therapy.
- A study analyzed data from 1,313 NMIBC patients to examine how smoking and systemic inflammation impact the effectiveness of BCG using a machine-learning algorithm.
- The results indicated that both smoking status and specific inflammatory markers can significantly predict the risk of disease progression, highlighting the need for tailored treatment strategies and further research to confirm the findings.
Blood Extracellular Vesicles Beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients.
Biomedicines
October 2024
Department of Molecular Medicine, "Sapienza" University of Rome, 00161 Rome, Italy.
Non-muscle-invasive bladder cancer (NMIBC) prognosis varies significantly due to the biological and clinical heterogeneity. High-risk stage T1-G3, comprising 15-20% of NMIBCs, involves the lamina propria and is associated with higher rates of recurrence, progression, and cancer-specific mortality. In the present study, we have evaluated the enumeration of tumour-derived extracellular vesicles (tdEVs) and circulating tumour cells (CTCs) in high-risk NMIBC patients and their correlation with survival outcomes such as time to progression (TTP), and cancer-specific survival (CSS).
View Article and Find Full Text PDFNew concept in urologic surgery: The total extended genital sparing radical cystectomy in women.
Arch Ital Urol Androl
May 2023
Department of Urology, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo.
Introduction And Objectives: The aim of the study was to evaluate genital sparing radical cystectomy surgery in female patients from the point of view of both oncologic and functional outcomes (with emphasis on urinary and sexual outcomes) in a single high-volume center for the treatment of muscular invasive bladder cancer.
Materials And Methods: Between January 2014 and January 2018, 14 female patients underwent radical cystectomy with preservation of genital organs (the entire vagina, uterus, fallopian tubes, ovaries) and orthotopic urinary neobladder (Padua neobladder). Inclusion criteria were recurrent T1G3 tumors; refractory tumors after BCG therapy without associated carcinoma in situ (CIS); T2 or T3a tumors entirely resected at endoscopic transurethral resection of the bladder and not involving urethra/bladder trigone.
Microbladder due to Granulomatous Cystitis Secondary to BCG Treatment.
Arch Esp Urol
October 2022
Departamento de Urología, Hospital Clínico Universitario de Valencia, Facultat de Medicina i Odontologia, Universitat de València, Valencia, España.
Introduction: Intravesical immunotherapy with bacillus Calmette-Guerin (BCG) is considered as the standard treatment for non-muscle invasive bladder cancer with high risk of recurrence and progression.
Objective: To report a case of granulomatous cystitis in a patient receiving BCG intravesical therapy for urothelial carcinoma.
Material And Methods: A 63-year-old man underwent BCG treatment for a bladder tumor with pathological diagnosis of T1G3 urothelial carcinoma.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!